Fenofibric acid reduces fibronectin and collagen type IV overexpression in human retinal pigment epithelial cells grown in conditions mimicking the diabetic milieu: Functional implications in retinal permeability

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 9, 2011, Pages 6348-6354

  Trudeau, Kyle ^a   Roy, Sumon ^a   Guo, Wen ^a   Hernández, Cristina ^b,c   Villarroel, Marta ^b,c   Simó, Rafael ^b,c   Roy, Sayon ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CLAUDIN 1; COLLAGEN TYPE 4; FENOFIBRIC ACID; FIBRONECTIN; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; GLUCOSE; INTERLEUKIN 1BETA; PROTEIN ZO1; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); DEXTRAN; DRUG DERIVATIVE; FENOFIBRATE; FLUORESCEIN ISOTHIOCYANATE; HYPOCHOLESTEROLEMIC AGENT; MEMBRANE PROTEIN; MESSENGER RNA; PHOSPHOPROTEIN; ZONULA OCCLUDENS-1 PROTEIN;

ARTICLE; BLOOD RETINA BARRIER; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DIABETES MELLITUS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; NUCLEOTIDE SEQUENCE; PERMEABILITY; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; CAPILLARY PERMEABILITY; CELL CULTURE; DOSE RESPONSE; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; METABOLISM; PHYSIOLOGY; UPREGULATION;

ANTICHOLESTEREMIC AGENTS; BLOTTING, WESTERN; CAPILLARY PERMEABILITY; CELLS, CULTURED; COLLAGEN TYPE IV; DEXTRANS; DIABETES COMPLICATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FENOFIBRATE; FIBRONECTINS; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GLUCOSE; HUMANS; INTERLEUKIN-1BETA; MEMBRANE PROTEINS; MICROSCOPY, CONFOCAL; PHOSPHOPROTEINS; RETINAL PIGMENT EPITHELIUM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SODIUM-POTASSIUM-EXCHANGING ATPASE; UP-REGULATION;

EID: 80053513862     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-7282     Document Type: Article

References (40)

1. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849-1861.
2. Keech AC, Mitchell P, Summanen PA, et al Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007;370:1687-1697.
3. Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363:233-244.
4. Simo R, Hernandez C. Fenofibrate for diabetic retinopathy. Lancet. 2007;370:1667-1668.
5. Guerin M, Bruckert E, Dolphin PJ, Turpin G, Chapman MJ. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 1996;16:763-772.
6. Koh KK, Han SH, Quon MJ, Yeal Ahn J, Shin EK. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care. 2005;28:1419-1424.
7. Yong QW, Thavintharan S, Cheng A, Chew LS. The effect of fenofibrate on insulin sensitivity and plasma lipid profile in nondiabetic males with low high density lipoprotein/dyslipidaemic syndrome. Ann Acad Med Singapore. 1999;28:778-782.
8. Filippatos T, Milionis HJ. Treatment of hyperlipidaemia with fenofibrate and related fibrates. Expert Opin Investig Drugs. 2008;17: 1599-1614.
9. Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Nakamura M. New insights into the pathophysiology of diabetic retinopathy: potential cell-specific therapeutic targets. Diabetes Technol Ther. 2000;2:601-608.
10. Cherian S, Roy S, Pinheiro A. Tight glycemic control regulates fibronectin expression and basement membrane thickening in retinal and glomerular capillaries of diabetic rats. Invest Ophthalmol Vis Sci. 2009;50:943-949.
11. Oshitari T, Polewski P, Chadda M, Li AF, Sato T, Roy S. Effect of combined antisense oligonucleotides against high-glucose-and diabetes-induced overexpression of extracellular matrix components and increased vascular permeability. Diabetes. 2006;55:86-92.
12. Roy S, Lorenzi M. Early biosynthetic changes in the diabetic-like retinopathy of galactose-fed rats. Diabetologia. 1996;39:735-738.
13. Evans T, Deng DX, Chen S, Chakrabarti S. Endothelin receptor blockade prevents augmented extracellular matrix component mRNA expression and capillary basement membrane thickening in the retina of diabetic and galactose-fed rats. Diabetes. 2000;49: 662-666.
14. Robison WG Jr, Jacot JL, Glover JP, Basso MD, Hohman TC. Diabetic-like retinopathy: early and late intervention therapies in galactose-fed rats. Invest Ophthalmol Vis Sci. 1998;39:1933-1941.
15. Lightman S, Towler HM. Diabetic retinopathy. Clin Cornerstone. 2003;5:12-21.
16. Simo R, Carrasco E, Garcia-Ramirez M, Hernandez C. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev. 2006;2:71-98.
17. Joussen AM, Smyth N, Niessen C. Pathophysiology of diabetic macular edema. Dev Ophthalmol. 2007;39:1-12.
18. Simo R, Villarroel M, Corraliza L, Hernandez C, Garcia-Ramirez M. The retinal pigment epithelium: something more than a constituent of the blood-retinal barrier-implications for the pathogenesis of diabetic retinopathy. J Biomed Biotechnol. 2010;2010:190724.
19. Ishibashi T, Kohno T, Sorgente N, Patterson R, Ryan SJ. Fibronectin of the chorioretinal interface in the monkey: immunohistochemical and immunoelectron microscopic studies. Graefes Arch Clin Exp Ophthalmol. 1985;223:158-163.
20. Karwatowski WS, Jeffries TE, Duance VC, Albon J, Bailey AJ, Easty DL. Preparation of Bruch's membrane and analysis of the agerelated changes in the structural collagens. Br J Ophthalmol. 1995;79:944-952.
21. Ida H, Ishibashi K, Reiser K, Hjelmeland LM, Handa JT. Ultrastructural aging of the RPE-Bruch's membrane-choriocapillaris complex in the D-galactose-treated mouse. Invest Ophthalmol Vis Sci. 2004; 45:2348-2354.
22. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979;76:4350-4354.
23. Abe T, Sugano E, Saigo Y, Tamai M. Interleukin-1beta and barrier function of retinal pigment epithelial cells (ARPE-19): aberrant expression of junctional complex molecules. Invest Ophthalmol Vis Sci. 2003;44:4097-4104.
24. Villarroel M, Garcia-Ramirez M, Corraliza L, Hernandez C, Simo R. Fenofibric acid prevents retinal pigment epithelium disruption induced by interleukin-1beta by suppressing AMP-activated protein kinase (AMPK) activation. Diabetologia. 2011;54(6):1543-1553.
25. Roy S, Sato T, Paryani G, Kao R. Downregulation of fibronectin overexpression reduces basement membrane thickening and vascular lesions in retinas of galactose-fed rats. Diabetes. 2003;52: 1229-1234.
26. Heth CA, Yankauckas MA, Adamian M, Edwards RB. Characterization of retinal pigment epithelial cells cultured on microporous filters. Curr Eye Res. 1987;6:1007-1019.
27. Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res. 2007;2007:95-103.
28. Gardner TW, Antonetti DA. Novel potential mechanisms for diabetic macular edema: leveraging new investigational approaches. Curr Diab Rep. 2008;8:263-269.
29. Chang CW, Ye L, Defoe DM, Caldwell RB. Serum inhibits tight junction formation in cultured pigment epithelial cells. Invest Ophthalmol Vis Sci. 1997;38:1082-1093.
30. Jin M, Barron E, He S, Ryan SJ, Hinton DR. Regulation of RPE intercellular junction integrity and function by hepatocyte growth factor. Invest Ophthalmol Vis Sci. 2002;43:2782-2790.
31. Miyamoto N, de Kozak Y, Jeanny JC, et al. Placental growth factor-1 and epithelial haemato-retinal barrier breakdown: potential implication in the pathogenesis of diabetic retinopathy. Diabetologia. 2007;50:461-470.
32. Gerhardinger C, Costa MB, Coulombe MC, Toth I, Hoehn T, Grosu P. Expression of acute-phase response proteins in retinal Muller cells in diabetes. Invest Ophthalmol Vis Sci. 2005;46:349-357.
33. Demircan N, Safran BG, Soylu M, Ozcan AA, Sizmaz S. Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye. 2006;20: 1366-1369.
34. Vincent JA, Mohr S. Inhibition of caspase-1/interleukin-1beta signaling prevents degeneration of retinal capillaries in diabetes and galactosemia. Diabetes. 2007;56:224-230.
35. Forsyth EA, Aly HM, Neville RF, Sidawy AN. Proliferation and extracellular matrix production by human infragenicular smooth muscle cells in response to interleukin-1 beta. J Vasc Surg. 1997; 26:1002-1007; discussion 1007-1008.
36. Yang WS, Kim BS, Lee SK, Park JS, Kim SB. Interleukin-1beta stimulates the production of extracellular matrix in cultured human peritoneal mesothelial cells. Perit Dial Int. 1999;19:211-220.
37. Chen LL, Zhang JY, Wang BP. Renoprotective effects of fenofibrate in diabetic rats are achieved by suppressing kidney plasminogen activator inhibitor-1. Vascul Pharmacol. 2006;44:309-315.
38. Hou X, Shen YH, Li C, et al. PPARα agonist fenofibrate protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress and MAPK activity. Biochem Biophys Res Commun. 2010;394:653-659.
39. Duhaney TA, Cui L, Rude MK, et al. Peroxisome proliferatoractivated receptor alpha-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload. Hypertension. 2007;49:1084-1094.
40. Kim J, Ahn JH, Kim JH, et al. Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway. Exp Eye Res. 2007;84:886-893.